...another iiBIG "Building Value Series©" Conference

After the success of our first two events in Chicago (April 2008) and Nashville (this past January) – with attendance of over 200 healthcare investment and industry executives from over 150 companies – Don’t miss out on this year’s 2009 mid-year event that will take place June 22-23 at the historic Drake Hotel in downtown Chicago:

www.iibig.com/F0904

---

Read what our attendees had to say about this past January’s Investment and M&A Opportunities in Healthcare – Nashville:

---

2009 Attendees Included Leading Healthcare, Finance, and Investment Executives from Organizations such as:

ABRY Partners Aequitas Capital All Med Alvarez & Marsal Ambient Healthcare AmMed Direct Apax Partners Aptium Oncology Bass, Berry & Sims PLC Benesch, Friedlander, Coplan & Aronoff LLP BlueCross BlueShield of Tennessee Bradley Arant Boult Cummings LLP Brentwood Capital Partners Camden Partners Capella Healthcare Capital BlueCross The Carlyle Group CCMP Capital Advisors Centerre Healthcare Coalition America Community Health Systems (CHS) Cornell University Covidien (formerly Tyco Healthcare) Crescent Healthcare Eos Partners Essent Healthcare Inc. The Financial Times, Mergermarket Division Fortress Investment Group Frazier Healthcare Ventures GE Healthcare Financial Services

General Atlantic Golden Gate Capital Gordian Health Great Point Partners Gresham Smith Harbert Venture Partners HCA Health Evolution Partners Healthcare Finance Group HealthLeaders Media HealthSpring Healthways Houlihan Lokey IBM Integrated Capital Services Limited ISIDA Private Hospital Jarrard Phillips Cate & Hancock, Inc. JRG Ventures Kaufman Hall & Associates, Inc. KeyBanc Capital Markets KPMG LLP Transaction Services KRG Capital Partners Lazard Middle Market Linden LLC Masterplan Metro Care Services, LLC Nashville Health Care Council National Renal Alliance Navigant Capital Advisors Navigant Consulting New Enterprise Associates

Ontario Teachers' Pension Plan Passport Health Peter J. Solomon Company PharmMD Pictet & Cie PricewaterhouseCoopers Prodigy Health Group Regent Surgical Health RehabCare Group ReMedPar River Cities Capital Funds Saint Louis University Santé Ventures Shattuck Hammond Partners Siemens Financial Services, Inc Signature Hospital Corporation Sonnenschein Nath & Rosenthal LLP Spectrum Equity Investors Spheris Stroudwater Associates Summit Partners TA Associates Inc. Technology Crossover Ventures The Tennessean UBS Vanderbilt University Medical Center Waller Lansden Dortch & Davis, LLP Western Kentucky Diagnostic Imaging Wood Creek Capital Management

---

List of Confirmed Speakers as of December 11, 2008

	Donald A. Adam, Senior Vice President & Chief Development Officer, RehabCare Group, Inc.		Christopher Kersey, M.D., Managing Member & Partner, Camden Partners
	Bo Bartholomew, CEO, PharmMd		Brian Kirkbride, Principal, Health Evolution Partners
	George W.Bishop, III, Partner, Waller Lansden		Jonathan C. Korngold, Managing Director, Head of Global Healthcare, General Atlantic, LLC
	Bradford C. Burkett, Managing Director, Investment Banking, Navigant Capital Advisors LLC		David Kosloff, Vice President, Frazier Healthcare Ventures
	Brian Canann, Vice President, The Caryle Group		Konstantin Lebedyev, Managing Director, Isida Private Hospital (Ukraine)
	Joe Cashia, CEO, National Renal Alliance		Thomas Mallon, Founder & CEO, Regent Surgical Health
	Michael S. Cole, Managing Director, Alvarez & Marsal		Rob Martin, Managing Partner, Excellere Partners
	J. Andrew Cowherd, Managing Director, Healthcare Group, Peter J. Solomon Company		Tom Milam, Chief Operating Officer, AmMed Direct
	Michael A. Crabb III, Managing Principal - Nashville, Stroudwater Associates		Michael O’Neil, Senior Vice President, Strategy & Development, HealthSpring
	Bruce Crosby, Senior Vice President, Corporate Development, Healthways, Inc.		David P. Osborn, Ph.D., Executive Director, Health Care Solutions Group, Vanderbilt University Medical Center
	Adam B. Dolder, Managing Director, Great Point Partners		Dr. Jonathan B. Perlin, President, Clinical Services and Chief Medical Officer, HCA
	Benjamin Edmands, Managing Director, CCMP Capital		Jim Quagliaroli, Principal, Spectrum Equity Investors
	Steven Elek, III, Partner-in-Charge, Healthcare Transaction Services, PricewaterhouseCoopers		Jon E. Santemma, Managing Director, Global Healthcare, Investment Banking Group, UBS
	Lars Enstrom, Managing Director, Fortress Investment Group LLC		Ryan Schwarz, Managing Director, The Carlyle Group
	Craig D Frances, M.D. Managing Director Summit Partners		Anu Singh, Vice President Kaufman Hall & Associates, Inc.
	Doug French, Managing Director, Santé Ventures		Maureen A. Spivack, Managing Director, Shattuck Hammond Partners
	Michael Froy, Partner, Sonnenschein Nath & Rosenthal LLP		Todd Squilanti, Senior Vice President, Corporate Development, Prodigy Health Group
	Bob Funari, Chairman & CEO, Crescent Healthcare		William W. Stead, MD, Associate Vice Chancellor for Strategy and Transformation & Director, Informatics Center, Vanderbilt University Medical Center
	Bruce D. Gardner, Americas Leader, Healthcare and Life Sciences, IBM General Business		John Titus, Partner, Bradley Arant Boult Cummings LLP
	Tim Gary, Senior Vice President & Chief Operating Officer, Gordian Health		Leigh Walton, Partner, Bass, Berry & Sims PLC
	Keith A. Gregg, MBA, CLP, Chairman & CEO, JRG Ventures		Tom C. Wylly II, Senior Partner, Brentwood Capital Advisors
	Buddy Gumina, Partner, Healthcare Sector Leader, Apax Partners, L.P.		Caroline Young, President, Nashville Health Care Council (NHCC)
	Russ Herakovich, Managing Director, Healthcare Financial Services, General Electric Corporation

---

OVERVIEW / SUMMARY:

A five-year study of Healthcare acquisition premiums depicts a dramatic upward trend. While valuations are high in all aspects of healthcare, companies with business models built around innovative technologies are trending slightly higher than those with service-delivery models.

Within the technology segment, biotech targets are commanding some of the highest premiums. Hear our experts explain why biotechnology deals are gaining ground and why cross-border deals are also on the rise. Foreign buyers, often with deep pockets, are making record investments into the U.S. health care industry through mergers and acquisitions.

While companies need to get more creative in financing deals in the current credit crisis, the primary reasons to chase health care mergers and acquisitions linger steadfastly in place: to merge disjointed providers to meet increasing demand in areas such as services and new technologies.

As a consequence, there is an M&A spending-spree underway. Since 2005, strategic acquisitions by pharmaceutical companies have exceeded $76 Billion. In 2005, there were 33 such deals amounting to $16.5 Billion – while in the first 9 months of 2007, 49 deals totaling $28.7 Billion were consummated! And financial buyers, led by private equity, hedge funds and other sophisticated investors are also continuing to play a big role in this space.

iiBIG’s Investment and M&A Opportunities in HEALTHCARE occurs at an exciting time for investors and other deal-makers seeking lucrative gains in 2009.

As 2008 comes to a close, deal value in the HEALTHCARE continues to increase. These results indicate strong activity in health care M&A despite the crisis that plagued the capital markets in the third quarter. The historically low dollar, coupled with downward pressure on valuations, has created many attractive opportunities in the U.S. market. The three sectors with the highest deal value in the Q3:08 are:

• Medical Devices – 32 deals, worth $525.80 million
• Biotechnology – 18 deals, $468.20 million
• Pharmaceuticals – 19 deals, $430.43 million